Loading...
Loading...
ABOS| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | -0.0M |
| Operating Expense | 32.3M |
| Operating I/L | -32.3M |
| Other Income/Expense | 2.5M |
| Interest Income | 3.5M |
| Pretax | -29.8M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -29.8M |
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of therapies for Alzheimer's disease. The company's primary focus is on advancing a targeted immunotherapy drug candidate, ACU193, a humanized monoclonal antibody in Phase I clinical-stage, designed to target soluble amyloid-beta oligomers. Through the development and potential commercialization of ACU193, Acumen Pharmaceuticals aims to generate revenue by providing a novel treatment option for Alzheimer's disease, addressing a significant unmet medical need in the market.
